The FDA enforcement report lists an ongoing Class III recall of buprenorphine sublingual tablets, 2 mg, in 30-tablet hospital unit-dose packs (3x10) packaged by American Health Packaging. The stated reason is a labelling error described as a label mix-up.
Class III is the lowest of the three FDA recall classes and means the agency judges use of the product unlikely to cause adverse health consequences. It is an administrative and quality action, not a safety finding about buprenorphine itself, and it does not change the drug's licensed indications or its place in opioid dependence treatment.
The practical exposure is narrow but real: unit-dose packs of this kind go to inpatient and institutional pharmacies rather than retail, and a mislabelled strength in a controlled drug used for opioid agonist therapy is the sort of error a ward can act on without questioning. Pharmacy will identify affected lots; the clinical job is to be unsurprised if a supply is withdrawn mid-admission and to have a plan for continuity of the patient's dose rather than an interruption.
This product is packaged for the American market and does not describe Indian supply. CDSCO has made no corresponding statement, and buprenorphine availability here is unaffected by this notice.
- Check with your inpatient pharmacy whether any affected American Health Packaging buprenorphine unit-dose stock is held
- Read the strength on the tablet card rather than the box for any controlled drug drawn from a unit-dose pack
- Have a continuity plan for opioid agonist therapy if a supply is withdrawn mid-admission — an interrupted dose risks withdrawal and disengagement
- Explain to patients that this is a packaging recall, not a problem with buprenorphine
- No action is needed for Indian supply; this notice concerns one American packager
Why it matters
A mislabelled controlled drug in a unit-dose pack is the kind of error that passes a ward check unchallenged.
Don't overread it
A Class III recall is a packaging and labelling action, not a safety finding about the drug.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for psychiatry, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free